Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 10, 2006. The report details a specific corporate action regarding the repurchase of the company's own shares, authorized by shareholders at the Annual General Meeting on May 17, 2006.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 1,825,000 Ordinary shares of 25 pence each.
- Purchase Date: November 10, 2006.
- Purchase Price: 1,359.25 pence per share.
- Treasury Shares Held: 218,514,678 shares (post-transaction).
- Shares in Issue: 5,770,641,223 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback program. The company acquired 1,825,000 shares to be held in Treasury, increasing its total Treasury holdings to approximately 218.5 million shares.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction.
Investor Verification Checklist
- Verify the total cost of the repurchase by multiplying 1,825,000 shares by 1,359.25 pence.
- Confirm the updated share capital structure (5,770,641,223 shares in issue) against subsequent filings.
- Review the Annual General Meeting minutes from May 17, 2006, to understand the full scope of the share buyback authorization.
- Note that this filing does not contain operational or financial performance data for the period.